Efavaleukin alfa

Generic Name
Efavaleukin alfa
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2049067-94-7
Unique Ingredient Identifier
YNH9K62UXU
Background

Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).

Associated Conditions
-
Associated Therapies
-

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2023-01-05
Last Posted Date
2024-11-27
Lead Sponsor
Amgen
Target Recruit Count
92
Registration Number
NCT05672199
Locations
🇺🇸

Santa Maria Gastroenterology Medical Group, Santa Maria, California, United States

🇺🇸

Indian Health Service Health Research, Kissimmee, Florida, United States

🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

and more 22 locations

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2021-08-03
Last Posted Date
2024-11-25
Lead Sponsor
Amgen
Target Recruit Count
224
Registration Number
NCT04987307
Locations
🇺🇸

Digestive Health Specialists of the Southeast, Dothan, Alabama, United States

🇺🇸

Birmingham Digestive Health Research, LLC, Homewood, Alabama, United States

🇺🇸

Arizona Health Research, Mesa, Arizona, United States

and more 197 locations

Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-08-03
Last Posted Date
2024-03-29
Lead Sponsor
Amgen
Target Recruit Count
32
Registration Number
NCT04987333
Locations
🇬🇧

Labcorp Clinical Research Unit - Leeds, Leeds, LDS, United Kingdom

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

First Posted Date
2020-12-23
Last Posted Date
2024-06-28
Lead Sponsor
Amgen
Target Recruit Count
168
Registration Number
NCT04680637
Locations
🇫🇷

Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse Cedex 9, France

🇯🇵

Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan

🇰🇷

Daegu Catholic Universtiy Medcial Center, Daegu, Korea, Republic of

and more 146 locations

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

First Posted Date
2018-03-01
Last Posted Date
2023-07-19
Lead Sponsor
Amgen
Target Recruit Count
35
Registration Number
NCT03451422
Locations
🇺🇸

Metroplex Clinical Research Center, Dallas, Texas, United States

🇺🇸

Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States

🇵🇱

Clinical Research Center Spzoo Medic-R Spolka Komandytowa, Poznan, Poland

and more 12 locations

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

First Posted Date
2018-02-06
Last Posted Date
2023-11-22
Lead Sponsor
Amgen
Target Recruit Count
32
Registration Number
NCT03422627
Locations
🇺🇸

Texas Oncology Baylor, Dallas, Texas, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇫🇷

Hôpital Saint Louis, Paris Cedex 10, France

and more 11 locations

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2018-01-25
Last Posted Date
2021-06-22
Lead Sponsor
Amgen
Target Recruit Count
36
Registration Number
NCT03410056
Locations
🇪🇸

Research Site, A Coruña, Galicia, Spain

© Copyright 2024. All Rights Reserved by MedPath